We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AKTX market cap is 8.86B. The company's latest EPS is USD -0.0023 and P/E is -517.39.
| Quarter End | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.55M | -4.33M | -1.46M | -5.9M | -5.24M |
| Net Income | -5.84M | -4.35M | -1.45M | -5.79M | -5.18M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 199k | 556k | 0 | 0 |
| Operating Income | -26.5M | -16.78M | -17.45M | -17.24M | -25.4M |
| Net Income | -19.95M | -16.85M | -17.08M | -17.42M | -17.01M |
| Quarter End | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 7.84M | 4.83M | 14.72M | 11.65M | 19.46M |
| Total Liabilities | 3.9M | 3.24M | 3.36M | 6.09M | 5.52M |
| Total Equity | 3.94M | 1.59M | 11.36M | 5.56M | 13.93M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 16.45M | 6.48M | 14.61M | 11.65M | 16.22M |
| Total Liabilities | 3.08M | 6.47M | 5.22M | 6.09M | 10.98M |
| Total Equity | 13.38M | 8k | 9.38M | 5.56M | 5.24M |
| Quarter End | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -7.42M | -12.28M | -13.84M | -18.85M | -5.05M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | N/A | 1.99M | 13.18M | 14.29M | 12.37M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -22.54M | -12.92M | -16.95M | -18.85M | -21.5M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 306k | 12.65M | 25.07M | 14.29M | 25.29M |
| Market Cap | 8.86B |
| Price to Earnings Ratio | -517.39 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 661.11 |
| Price to Book Ratio | 1.69k |
| Dividend Yield | - |
| Shares Outstanding | 7.44B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.37 (25%) |
| Company Name | Akari Therapeutics PLC |
| Address |
highdown house yeoman west sussex BN99 3HH |
| Website | https://www.akaritx.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
